We’re proud to welcome Peter W. Marks, MD, PhD, Director, CBER, U.S. FDA, who is joining us for this final webinar in 2020 PDA Advanced Therapy Medicinal Products Month Webinar Series!
As more and more companies are transitioning into cell and gene manufacturing, it is imperative that regulatory requirements allow for an acceptable risk-based approach that can be applied across manufacturing sites.
This webinar will highlight global regulatory challenges, current regulatory thinking, and efforts that are being proposed and/or undertaken to promote convergence in global regulatory approaches for cell and gene therapy manufacturing.
In addition to the presentation by Dr. Marks, we will be hearing an industry perspective on lessons learned from an RMAT designation request.
Following the presentations, get your questions answered during a live 30-minute Q&A session with the speakers.
This webinar is presented as part of the 2020 PDA Advanced Therapy Medicinal Products Month.